Projects

RNDr. Silvia Tyčiaková, PhD.

International

Current
  • Nanobiotechnologies for Innovative Therapeutic Approaches for Cancer
    Program: Horizon Europe
    Duration: 1. 11. 2023 – 31. 10. 2028
  • International networking on in vitro colon models simulating gut microbiota mediated interactions
    Program: COST
    Duration: 9. 10. 2024 – 8. 10. 2028
Finished
  • A4L_BRIDGE Understanding the link between ECM synthesis, the carbonic anhydrase I, and tumorigenicity
    Program: Other
    Duration: 1. 11. 2024 – 31. 10. 2025
  • Targeted combination therapy of colon cancer with therapeutic gene/drug loaded novel dendritic nanocarriers
    Program: Bilateral - other
    Duration: 3. 9. 2018 – 30. 11. 2022

National

Current
  • Carbonic anhydrase I and cancer cell tumorigenicity
    Program: VEGA
    Duration: 1. 1. 2025 – 31. 12. 2028
  • Identification of novel biomarkers linked to the relapse of metastatic colorectal cancer after metastasectomy
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
  • Verification of clinically relevant biomarkers for the stratification of CRC patients by molecular and bioinformatic methods.
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
Finished
  • Identification of new treatment options in refractory testicular germ cell tumors
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
  • Interactions of calcium transport systems in carcinogenesis
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
  • The role of mitochondria in progression of colorectal cancer
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Identification of chemoresistant cell populations with metastatic potential in colorectal carcinoma
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Markers overlapping chemoresistance and metastatic potential in colorectal cancer - aldehyde dehydrogenase and its clinical relevance
    Program: Other projects
    Duration: 1. 11. 2019 – 31. 12. 2022
  • TArgetiNg Dna mEthylation by epigenetic editing and its implementation into personalised diagnostics and therapy of uveal Melanoma
    Program: SRDA
    Duration: 1. 8. 2018 – 31. 12. 2022
  • Mechanism of the mesenchymal stromal cell-induced tolerance to antitumor treatment and targeted therapeutic intervention in the breast cancer cells
    Program: SRDA
    Duration: 1. 7. 2017 – 31. 12. 2021
  • Study of the mechanisms blocking tumorigenicity of cancer cells overexpressing human tumor necrosis factor alpha.
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Analysis of matrix metalloproteinase induction in association with expression of HLA-G molecules
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2017
  • Mechanisms of interactions and bystander effect mediated by mesenchymal stromal cells expressing prodrug-converting genes on tumour stem cells
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • Cytotoxic Effect of Engineered Mesenchymal Stromal Cells on Human Chemoresistant Tumour Cells and Cancer Stem Cells
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Reversion of chemoresistance of human cancer stem cells
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Targeted Augmented Cellular Therapy against Tumor Initiating and Chemoresistant Cells
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • Molecular mechanisms of tumor-driven mesenchymal stromal cells‘ differentiation
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
  • Gene-cell therapy of cancer using a self-inactivating - retroviral vectors inducibly expressing tumour necrosis factor alpha in human mesenchymal stem cells
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Identification of alternative protein partners of tumor suppressors from INK4 family
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Human mesenchymal stem cells as cytoreagents for metastasis-targeted therapy
    Program: SRDA
    Duration: 1. 6. 2008 – 30. 6. 2011
  • Biological effect of novel RET gene mutation connected to multiple endocrine neoplasia type 2
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Implementation of histology and molecular-biology methods in the tumor heterogenity analysis
    Program: Intra-constitutional
    Duration: 1. 1. 2010 – 31. 12. 2010
  • Mutations of ret proto-oncogene connected with thyroid carcinomas
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees